{"denoms":[{"counts":[{"groupId":"BG000","value":"57"},{"groupId":"BG001","value":"156"},{"groupId":"BG002","value":"77"},{"groupId":"BG003","value":"290"}],"units":"Participants"}],"groups":[{"description":"Patients with gross total resection (GTR)/no evidence of metastatic (M0) medulloblastoma, nodular desmoplastic or high grade glioma histology will receive induction chemotherapy and low-risk therapy.","id":"BG000","title":"Low-Risk Group"},{"description":"Patients with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease, will receive induction chemotherapy and intermediate-risk therapy.","id":"BG001","title":"Intermediate-Risk Group"},{"description":"Patients with central nervous system (CNS) metastatic disease will receive induction chemotherapy and high-risk therapy.","id":"BG002","title":"High-Risk Group"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.0","value":"17.0"},{"groupId":"BG001","spread":"12.8","value":"22.9"},{"groupId":"BG002","spread":"10.4","value":"19.3"},{"groupId":"BG003","spread":"11.9","value":"20.8"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"months"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"0.2","upperLimit":"35.2","value":"16.1"},{"groupId":"BG001","lowerLimit":"1.8","upperLimit":"60.6","value":"21.9"},{"groupId":"BG002","lowerLimit":"0.9","upperLimit":"36.9","value":"20.0"},{"groupId":"BG003","lowerLimit":"0.2","upperLimit":"60.6","value":"20.1"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"months"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"66"},{"groupId":"BG002","value":"43"},{"groupId":"BG003","value":"131"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"90"},{"groupId":"BG002","value":"34"},{"groupId":"BG003","value":"159"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"7"}],"title":"Mexican/Chicano"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"30"}],"title":"NOS Spanish, Hispanic, Latino"},{"measurements":[{"groupId":"BG000","value":"47"},{"groupId":"BG001","value":"120"},{"groupId":"BG002","value":"64"},{"groupId":"BG003","value":"231"}],"title":"Non Spanish speaking, Non Hispanic"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"4"}],"title":"Puerto Rican"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"}],"title":"South or Central American"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"16"}],"title":"Unknown"}],"title":"Ethnicity"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}],"title":"American Indian/Alaskan/White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}],"title":"American Indian/Alaskan Native"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"10"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"4"}],"title":"Asian and White"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"30"}],"title":"Black"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}],"title":"Black and White"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"9"}],"title":"Multiple Race (NOS)"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"7"}],"title":"Other"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}],"title":"Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"6"}],"title":"Unknown"},{"measurements":[{"groupId":"BG000","value":"41"},{"groupId":"BG001","value":"118"},{"groupId":"BG002","value":"61"},{"groupId":"BG003","value":"220"}],"title":"White"}],"title":"Race"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"Participants were patients with newly diagnosed tumors of the CNS, including medulloblastoma, supratentorial primitive neuroectodermal tumor (PNET), pineoblastoma, atypical teratoid rhabdoid tumor (ATRT), choroid plexus carcinoma, ependymoma, and high-grade glioma. All eligible patients enrolled were included in the baseline characteristics."}